protandim glp 1 MyGLP-1™ ProClinical Support – Purity Products LifeVantage - LifeVantage added a

GLP-1 receptor agonists may improve psoriatic skin disease through combined metabolic and immunomodulatory effects Observational studies show reductions in PASI scores, with improvements of approximately 40% to 80% Treatment is associated with better patient-reported quality of life Benefits extend beyond glycemic control and weight loss Agents such as semaglutide and liraglutide reduce inflammatory markers, including C-reactive protein and interleukin-6 Improvements in lipid profile and reductions in visceral fat have been reported Psoriasis improvement may correlate with reduced superficial adiposity and decreased dermal T-cell density GLP-1 receptor agonists can be safely combined with methotrexate, cyclosporine, and biologic therapies The safety profile is generally favorable, with mostly transient gastrointestinal side effects Serious adverse events such as pancreatitis and gallbladder complications are rare but require monitoring MSc

Nevertheless, the research and development of GLP-1R agonists provide new perspectives and strategies for the treatment of diabetes, obesity, and related complications

A licensed provider must review your thyroid history, lab results, medications, contraindications, and treatment goals before deciding whether GLP-1 therapy is appropriate

Data Usage: You consent to our Privacy Policy

Article highlights - GLP-1 receptor agonists cause gastrointestinal symptoms, but these effects do not usually cause discontinuation of therapy